Catalym

CatalYm is a clinical-stage biotech developing visugromab, a first-in-class antibody neutralizing GDF-15, a key driver of immune evasion in cancer. The program has shown durable responses in refractory solid tumors in combination with anti-PD-1 and is advancing in NSCLC, HCC, and urothelial cancer – with additional potential in cancer cachexia.